Immunotherapy

Using Autologous Tumor-Infiltrating Lymphocytes to Mediate Tumor Regression: Promising Outcomes in Experimental Research

Using Autologous Tumor-Infiltrating Lymphocytes to Mediate Tumor Regression: Promising Outcomes in Experimental Research

By

Experimental research may provide a blue print for the treatment of many types of cancer.

Late-Onset Toxicity Possible With Immunotherapy

Late-Onset Toxicity Possible With Immunotherapy

By

Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

By

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

Does SBRT Improve the Pembrolizumab Response Rate?

Does SBRT Improve the Pembrolizumab Response Rate?

By

Although checkpoint inhibition is altering the landscape of oncologic care, there is a low response rate to treatment.

Lung Cancer: FDA Collaboration Highlights Real-world Immunotherapy Treatment Patterns

Lung Cancer: FDA Collaboration Highlights Real-world Immunotherapy Treatment Patterns

By

Study findings suggest that some clinicians are using immunotherapies in the types of patients not included in clinical trials.

ctDNA Sequencing Predicts Likelihood of Immunotherapy Response

ctDNA Sequencing Predicts Likelihood of Immunotherapy Response

By

Researchers collected ctDNA samples from patients with varying cancer types to determine whether liquid biopsies may help to predict response to checkpoint inhibition.

Knowledge of Immunotherapies in Melanoma Continues to Grow

Knowledge of Immunotherapies in Melanoma Continues to Grow

By

Clinicians continue to learn about which patients will benefit most from different immunotherapy treatments, and how dosing can effect adverse events.

Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma

Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma

By

After the second interim analysis, an external data monitoring committee recommended that pembrolizumab be made available to patients receiving ipilimumab whose disease had progressed despite treatment.

Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

By

Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is unlikely to work for patients with the disease?

Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer

Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer

By

One (4.2%) patient achieved complete response, and 7 patients (29.2%) achieved durable partial responses. The overall response rate (ORR) was 33.3% (95% CI, 15.6%-55.3%).

Melanoma Vaccine Trial Yields Promising Results

Melanoma Vaccine Trial Yields Promising Results

By

Developments in deep sequencing genomic technologies and bioinformatics have made it possible to identify mutations in melanoma and to predict targetable neoantigens.

Nivolumab Approved for Metastatic Colorectal Cancer

Nivolumab Approved for Metastatic Colorectal Cancer

By

Nivolumab demonstrated an overall response rate of 32% in all patients, including 2 patients who exhibited a complete response and 22 patients who had partial responses.

Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma

Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma

By

Researchers at the University of Miami in Florida are evaluating whether a partially matured dendritic cell vaccine is safe and effective for patients with glioma or glioblastoma.

Q&A With Roberto Iacovelli, MD: Personalizing Immunotherapy for Renal Cell Carcinoma

Q&A With Roberto Iacovelli, MD: Personalizing Immunotherapy for Renal Cell Carcinoma

By

In this question-and-answer session, Cancer Therapy Advisor asked Dr Iacovelli about his team's recent review regarding the future of personalizing immunotherapy for RCC.

Nivolumab and Ipilimumab Well-tolerated, Active in Metastatic Renal Cell Carcinoma

Nivolumab and Ipilimumab Well-tolerated, Active in Metastatic Renal Cell Carcinoma

By

Combining nivolumab with ipilimumab is safe, efficacious, and potentially improves overall survival among patients with metastatic renal cell carcinoma.

Nivolumab Does Not Prolong Overall Survival in Advanced Melanoma Post-ipilimumab

Nivolumab Does Not Prolong Overall Survival in Advanced Melanoma Post-ipilimumab

By

Nivolumab, a monoclonal antibody targeting PD-1, does not improve OS among patients with advanced melanoma whose disease progresses after receiving ipilimumab.

Immunotherapy of Advanced Colorectal Cancer By Enlisting Bystander T Cells

Immunotherapy of Advanced Colorectal Cancer By Enlisting Bystander T Cells

By

Study results presented at ASCO point to a major advance for immune therapy in advanced CEA-expressing CRC and possibly other CEA-expressing malignancies.

Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach

Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach

By

Vaccines targeting multiple myeloma antigens offer a promising therapeutic approach by helping the immune system to fight off cancer cells.

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

By

Maintenance pembrolizumab does not prolong progression-free survival, though it may improve overall survival, among patients with extensive-stage small-cell lung cancer.

Promising Activity Reported for Nivolumab in Gynecologic Cancers

Promising Activity Reported for Nivolumab in Gynecologic Cancers

By

Nivolumab, a programmed death (PD)-1 inhibitor, showed promising clinical activity in recurrent or metastatic cervical cancers and provides a promising new approach to treatment.

Lung Cancer Radiotherapy Might Improve Immune Checkpoint Blockade-associated Survival

Lung Cancer Radiotherapy Might Improve Immune Checkpoint Blockade-associated Survival

By

Researchers call for additional clinical trials investigating radiotherapy followed by immune checkpoint blockade for patients with NSCLC.

Neoadjuvant Nivolumab Shows Efficacy in Non-small Cell Lung Cancer

Neoadjuvant Nivolumab Shows Efficacy in Non-small Cell Lung Cancer

By

Neoadjuvant nivolumab is safe and provides a comparable pathologic response to that with cisplatin-based neoadjuvant chemotherapy in resectable non-small cell lung cancer.

Immune Checkpoint Inhibitors: Treatment Efficacy in Elderly Patients With Melanoma

Immune Checkpoint Inhibitors: Treatment Efficacy in Elderly Patients With Melanoma

By

Immune checkpoint inhibitors may be effective for treating elderly patients with melanoma without dramatically increasing toxicity.

Lung Cancer Treatment Shows Promise With TG4010 and CIMAvax-EGF Vaccine Therapies

Lung Cancer Treatment Shows Promise With TG4010 and CIMAvax-EGF Vaccine Therapies

By

Two vaccine therapies, TG4010 and CIMAvax-EGF, show promise for treating lung cancer. Developed and approved for use in Cuba, CIMAvax-EGF is now undergoing clinical study in the United States.

Pembrolizumab May Effectively Treat Mediastinal B Cell Lymphoma

Pembrolizumab May Effectively Treat Mediastinal B Cell Lymphoma

By

Pembrolizumab may be an effective treatment for patients with a rare subtype of diffuse large B-cell lymphoma, which usually carries a poor prognosis.

Pembrolizumab Approved for Previously Untreated Non-small Cell Lung Cancer

Pembrolizumab Approved for Previously Untreated Non-small Cell Lung Cancer

By

The FDA approved pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic lung cancer.

Second-line Atezolizumab Fails To Prolong Survival in Advanced Urothelial Cancer

Second-line Atezolizumab Fails To Prolong Survival in Advanced Urothelial Cancer

By

It's unclear whether the FDA will revoke its May 2016 approval of atezolizumab, which was based on tumor response rate and duration of response in the phase 2 open-label IMvigor210 study.

Endometrial Cancer: Some Durable Responses to Pembrolizumab

Endometrial Cancer: Some Durable Responses to Pembrolizumab

By

A subset of patients with advanced endometrial cancer experienced durable partial responses to pembrolizumab.

Ovarian/Breast Cancer Vaccine Research Looks To Establish Therapeutic Efficacy

Ovarian/Breast Cancer Vaccine Research Looks To Establish Therapeutic Efficacy

By

Researchers are developing vaccines for patients with ovarian or breast cancer, with timing and vector being increasingly important factors for establishing therapeutic efficacy.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs